394.00p+11.00 (+2.87%)17 Jan 2025, 17:15
Jump to:
Maxcyte INC Fundamentals
Company Name | Maxcyte INC | Last Updated | 2025-01-17 |
---|---|---|---|
Industry | Medical Devices | Sector | Healthcare |
Shares in Issue | 105.483 m | Market Cap | £415.60 m |
PE Ratio | 0.00 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | -$0.37 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0.0737 | Debt Equity Ratio | 0.0816 |
Asset Equity Ratio | 1.1655 | Cash Equity Ratio | 0.7212 |
Quick Ratio | 8.9888 | Current Ratio | 9.81 |
Price To Book Value | 2.3838 | ROCE | 0 |
Maxcyte INC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Maxcyte INC Company Financials
Assets | 2023 | 2022 |
---|---|---|
Tangible Assets | $34.75 m | $33.58 m |
Intangible Assets | 0 | 0 |
Investments | 0 | 0 |
Total Fixed Assets | $78.08 m | $34.39 m |
Stocks | $12.23 m | $8.58 m |
Debtors | 0 | 0 |
Cash & Equivalents | $168.29 m | $227.34 m |
Other Assets | 0 | 0 |
Total Assets | $268.27 m | $286.65 m |
Liabilities | 2023 | 2022 |
---|---|---|
Creditors within 1 year | $17.86 m | $15.43 m |
Creditors after 1 year | $18.25 m | $17.26 m |
Other Liabilities | 0 | 0 |
Total Liabilities | $36.11 m | $32.69 m |
Net assets | $232.17 m | $253.97 m |
Equity | 2023 | 2022 |
---|---|---|
Called up share capital | $1.04 m | $1.02 m |
Share Premium | $406.93 m | $390.82 m |
Profit / Loss | -$37.92 m | -$23.57 m |
Other Equity | $232.17 m | $253.97 m |
Preference & Minorities | 0 | 0 |
Total Capital Employed | $232.17 m | $253.97 m |
Ratios | 2023 | 2022 |
---|---|---|
Debt Ratio | $0.07 | $0.06 |
Debt-to-Equity | $0.08 | $0.06 |
Assets / Equity | 1.1655 | 1.1655 |
Cash / Equity | 0.7212 | 0.7212 |
EPS | -$0.37 | -$0.23 |
Cash Flow | 2023 | 2022 |
---|---|---|
Cash from operating activities | -$21.69 m | -$14.78 m |
Cashflow before financing | -$19.54 m | -$11.89 m |
Increase in Cash | $35.44 m | -$36.72 m |
Income | 2023 | 2022 |
---|---|---|
Turnover | $41.29 m | $44.26 m |
Cost of sales | $4.74 m | $5.10 m |
Gross Profit | $36.55 m | $39.16 m |
Operating Profit | -$48.30 m | -$27.36 m |
Pre-Tax profit | -$37.92 m | -$23.57 m |
Maxcyte INC Company Background
Sector | Healthcare |
---|---|
Activities | MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |
Latest Interim Date | 6 Aug 2024 |
Latest Fiscal Year End Date | 12 Mar 2024 |
Maxcyte INC Directors
Appointed | Name | Position |
---|---|---|
Invalid DateTime | Ms. Cynthia Lynne Collins | Director |
2024-03-15 | Mr. Douglas J Swirsky | CHIEF FINANCIAL OFFICER |
Invalid DateTime | Mr. Stanley Charles Erck | Non-Executive Director |
Invalid DateTime | Mr. Patrick J Balthrop Sr | Non-Executive Director |
Invalid DateTime | Dr. Richard H. Douglas, PhD | Non-Executive Director |
Invalid DateTime | Mr. Arthur Michael Mandell | Independent Director |
Invalid DateTime | Mr. John Joseph Johnston | Non-Executive Director |
Invalid DateTime | Dr. Yasir B. Al-Wakeel | Non-Executive Director |
Invalid DateTime | Mr. Douglas Arthur Doerfler | Executive Director,President and Chief Executive Officer |
Invalid DateTime | Mr. William Wade Brooke | Non-Executive Director |
Invalid DateTime | Ms. Rekha Hemrajani, M.B.A. | Non-Executive Director |
2022-03-25 | Ms. Amanda L. Murphy | Chief Financial Officer |
2024-08-01 | Mr. Thomas M. Ross | EVP, GLOBAL SALES |
Invalid DateTime | Mr. Maher Masoud | Executive Director,President and Chief Executive Officer |
2022-04-11 | Mr. Cenk Sumen | Chief Scientific Officer |
2025-01-13 | Mr. David I. Sandoval | GENERAL COUNSEL |
2024-09-16 | Mr. Ali Soleymannezhad | Chief Commercial Officer |
Maxcyte INC Contact Details
Company Name | MaxCyte Inc |
---|---|
Address | 22 Firstfield Road, Suite 110, Gaithersburg, 20878 |
Telephone | +1 301 944-1700 |
Website | https://www.maxcyte.com |
Maxcyte INC Advisors
Registrar | Capita Asset Services |
---|---|
Phone | +44 1534847000 |
Fax | +44 1534847001 |
Auditor | Aronson LLC |
---|---|
Phone | +1 301 231-6200 |
Fax | +1 301 231-7630 |
Solicitor | Cooley LLP |
---|---|
Phone | +1 703 456-8000 |
Financial PR Adviser | Consilium Strategic Communications |
---|---|
Phone | +44 2037095700 |
Solicitor | Feldhaus Law Group, P.C. |
---|
Solicitor | Travers Smith LLP |
---|---|
Phone | +44 2072953000 |
Fax | +44 2072953500 |
Solicitor | Norton Rose Fulbright US LLP |
---|
Nominated Adviser | Panmure Gordon (UK) Ltd |
---|---|
Phone | +44 2078862500 |
Stockbroker | Panmure Gordon (UK) Ltd |
---|---|
Phone | +44 2078862500 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Big Yellow Group PLC | 932.00 | 7.00 |
Ferrexpo PLC | 108.40 | 6.90 |
Aston Martin Lagonda Global Holdings PLC | 108.60 | 6.47 |
Entain PLC | 669.60 | 6.29 |
Smiths Group PLC | 1,862.00 | 5.50 |
Discoverie Group PLC | 694.00 | 4.99 |
Fallers
Company | Price | % Chg |
---|---|---|
Bakkavor Group PLC | 143.00 | -4.03 |
Herald Investment Trust PLC | 2,400.00 | -3.81 |
Hochschild Mining PLC | 220.50 | -3.29 |
W.A.G Payment Solutions PLC | 84.00 | -3.23 |
North Atlantic Smaller Companies Investment Trust PLC | 3,670.00 | -3.17 |
Bridgepoint Group PLC | 358.40 | -3.14 |
Risers/fallers data from previous trading day.